PDL BioPharma, Inc. (PDLI) News
Filter PDLI News Items
PDLI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PDLI News From Around the Web
Below are the latest news stories about Pdl Biopharma Inc that investors may wish to consider to help them evaluate PDLI as an investment opportunity.
Silver Point Capital L.P. Acquires 640,000 Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) StockPDL BioPharma, Inc. (NASDAQ:PDLI) major shareholder Silver Point Capital L.P. bought 640,000 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The stock was purchased at an average cost of $2.62 per share, with a total value of $1,676,800.00. The acquisition was disclosed in a filing with the Securities & […] |
Is PDLI A Good Stock To Buy Now?Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […] |
PDL BioPharma enters Capital Provision Agreement with Epps InvestmentsPDL BioPharma ([[PDLI]] +5.2%) has entered into a Capital Provision Agreement with Epps Investments LLC. Under the terms, Epps to pay PDL ~$51.39M no later than December 31, 2020, in exchange for 100% of the payments received by PDL on or after the date of the Agreement pursuant to the... |
PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with WellstatPDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than December 31, 2020, in exchange for 100% of the payments or other property or value received by PDL on or after the date of the Agreement pursuant to the settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC) ("Wellstat Diagnostics") announced August 12, 2020, and the underlying claims resolved by the Settlement Agreement. The Settlement Agreement resolved previously reported litigation relating to loans made to Wellstat Diagnostics by PDL. PDL has agreed to ... |
PDL Announces Timeline for Voluntarily Delisting from NasdaqINCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq")…. |
David W. Gryska Sells 75,000 Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) StockPDL BioPharma, Inc. (NASDAQ:PDLI) Director David W. Gryska sold 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 3rd. The shares were sold at an average price of $2.52, for a total value of $189,000.00. Following the completion of the sale, the director now owns 30,337 shares in the company, […] |
PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business UpdatePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to Wednesday, November 11, 2020. PDL will issue its third quarter 2020 financial results news release on November 11 after market close, and PDL's management will host a conference call and webcast that same day at 4:30 p.m. Eastern time to discuss those financial results and provide an update on its progress in monetizing the Company's assets. A slide presentation to accompany the call will be available via the webcast link on the PDL website at http://www.pdl.com/. |
PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […] |
Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […] |
PDL BioPharma Completes Spin-Off of LENSARPDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR"). |